FDA
-
-
-
-
-
-
-
FDA accepts Axsome drug application for cataplexy treatment
-
-
-
-
-
-
-
Axsome Therapeutics Highlights the Importance of Brain Health During Alzheimer's & Brain Awareness Month
-
-
-
-
-
-
-
Axsome Therapeutics Announces Settlement Resolving All SUNOSI® (solriamfetol) Patent Litigation
-
-
-
-
-
-
-
Axsome Therapeutics (AXSM) PT Raised to $260 at Guggenheim
-
-
-
-
-
-
-
Axsome Therapeutics Announces FDA Approval of AUVELITY® (dextromethorphan HBr and bupropion HCl) for the Treatment of Agitation Associated with Dementia due to Alzheimer’s Disease
-
-
-
-
-
-
-
Axsome Therapeutics to Participate in Upcoming Investor Conferences
-
-
-
-
-
-
-
Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23
-
330,085 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

